Next Article in Journal
Biochemical Assessment of Coenzyme Q10 Deficiency
Previous Article in Journal
Mitochondrial Modification Techniques and Ethical Issues
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
J. Clin. Med. 2017, 6(3), 26;

Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations

Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA
Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA
Division of Vascular and Interventional Radiology, Mayo Clinic, Phoenix, AZ 85054, USA
Division of Oncology, Mayo Clinic, Phoenix, AZ 85054, USA
Department of Radiology, Ankara Oncology Training and Research Hospital, Ankara, Turkey
Division of Transplant Surgery, Mayo Clinic, Phoenix, AZ 85054, USA
Author to whom correspondence should be addressed.
Academic Editor: Bernhard Rauch
Received: 29 November 2016 / Revised: 12 February 2017 / Accepted: 21 February 2017 / Published: 1 March 2017
Full-Text   |   PDF [1957 KB, uploaded 1 March 2017]   |  


We characterized the effect of systemic therapy given after portal vein embolization (PVE) and before hepatectomy on hepatic tumor and functional liver remnant (FLR) volumes. All 76 patients who underwent right PVE from 2002–2016 were retrospectively studied. Etiologies included colorectal cancer (n = 44), hepatocellular carcinoma (n = 17), cholangiocarcinoma (n = 10), and other metastases (n = 5). Imaging before and after PVE was assessed. Chart review revealed systemic therapy administration, SNaPshot genetic profiling, and comorbidities. Nine patients received systemic therapy; 67 did not. Tumor volume increased 28% in patients who did not receive and decreased −24% in patients who did receive systemic therapy (p = 0.026), with no difference in FLR growth (28% vs. 34%; p = 0.645). Among 30 patients with genetic profiling, 15 were wild type and 15 had mutations. Mutations were an independent predictor of tumor growth (p = 0.049), but did not impact FLR growth (32% vs. 28%; p = 0.93). Neither cirrhosis, hepatic steatosis, nor diabetes impacted changes in tumor or FLR volume (p > 0.20). Systemic therapy administered after PVE before hepatic lobectomy had no effect on FLR growth; however, it was associated with decreasing tumor volumes. Continuing systemic therapy until hepatectomy may be warranted, particularly in patients with genetic mutations. View Full-Text
Keywords: portal vein embolization; angiography; embolization; chemotherapy; mutation portal vein embolization; angiography; embolization; chemotherapy; mutation

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Deipolyi, A.R.; Zhang, Y.S.; Khademhosseini, A.; Naidu, S.; Borad, M.; Sahin, B.; Mathur, A.K.; Oklu, R. Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations. J. Clin. Med. 2017, 6, 26.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top